

SINGAPORE PAINCARE HOLDINGS LIMITED

Company Registration No.:201843233N
(Incorporated in the Republic of Singapore)

REALLOCATION AND UPDATE ON THE USE OF PROCEEDS FROM THE INITIAL PUBLIC OFFERING AND PRIVATE PLACEMENT

The Board of Directors (“**Board**”) of Singapore Paincare Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) refers to the Company’s initial public offering (“**IPO**”) offer document dated 13 July 2020 (“**Offer Document**”) in connection with its IPO and, the Company’s announcements dated

- (i) 17 November 2020, 23 November 2020 and 27 November 2020 in relation to the proposed subscription of 18,000,000 new ordinary shares in the issued share capital of the Company (the “**Placement**”) by Sian Chay Medical Institution;
- (ii) 30 November 2020 and 2 December 2020 in relation to the proposed acquisition of 40% of the total issued share capital of KCS Anaesthesia Services Pte. Ltd and the re-allocation of use of proceeds from the IPO;
- (iii) 14 March 2023 in relation to the acquisition of 100% of the total issued share capital of PTL Spine & Orthopaedics Private Limited and the reallocation of use of proceeds from the Placement; and
- (iv) 1 July 2023 in relation to the acquisition of the total issued share capital of Boon Lay Clinic and Surgery Pte Ltd and the use of IPO proceeds

(collectively, the “**Announcements**”).

The Board wishes to update that the remaining balance of S\$41,000 to be used to expand business operations locally and regionally from the IPO proceeds had been utilised as the start-up capital for the newly incorporated subsidiary, Alexandra Medical and Paincare Clinic Pte. Ltd. (“**Alexandra**”).

Further, the Board also wishes to announce that after a review of the Group’s cashflow, operational requirements and expansion plans, the Board has decided to reallocate a portion of the proceeds from the Placement that was originally allocated for the expansion of the range of pain care services to be used to expand business operations locally and regionally (the “**Reallocation**”). The utilisation of the reallocated amount of \$728,000, is as detailed in the table entitled “Use of proceeds from the Placement” below.

The Board is of the view that the Reallocation is in the best interests of the Group and its shareholders as this will help improve the Group’s working capital position amidst the current challenging economic environment.

Following the above-mentioned, the following tables summarise the utilisation of the net proceeds from the IPO and the Placement as at the date of this announcement:

Use of IPO proceeds

Use of net proceeds	Amount allocated (S\$'000)	Amount allocated after reallocation ⁽¹⁾ (S\$'000)	Amount utilised as at the date of this announcement (S\$'000)	Balance of net proceeds as at the date of this announcement (S\$'000)
Expand range of pain care services	1,100	100	-	100
Expand business operations locally and regionally	1,400	3,441	(3,441) ⁽²⁾	-
Working capital	1,041 ⁽¹⁾	-	-	-
Total	3,541	3,541	(3,441)	100

Notes:

- (1) (a) S\$1.041 million of the net proceeds initially allocated for the Group's working capital had been reallocated to expand the Group's business operations locally and regionally, and (b) S\$1.0 million of the net proceeds initially allocated for the Group's expansion of its range of pain care services had been reallocated to expand the Group's business operations locally and regionally. Please refer to the Company's announcements dated 30 November 2020 and 1 July 2023 for more details.
- (2) (a) Utilised for the acquisition of 40% of the total issued share capital of KCS amounting to S\$2.4 million, (b) the acquisition of 100% of the total issued share capital of Boon Lay Clinic and Surgery Pte. Ltd amounting to S\$1.0 million, and (c) startup capital expenses for the newly incorporated subsidiary, Alexandra, amounting to S\$0.041 million.

Save as disclosed above and in the Announcements, the above utilisation is in accordance with the intended use as stated in the Offer Document dated 13 July 2020.

Use of proceeds from the Placement

	Amount allocated (S\$'000)	Amount allocated pursuant to the Reallocation (S\$'000)	Amount Utilised (S\$'000)	Balance (S\$'000)
To expand the range of pain care services	1,975	100 ⁽¹⁾	-	100
To expand business operations locally and regionally	1,975	3,850 ⁽¹⁾	(3,850) ⁽²⁾	-
Total	3,950	3,950	(3,850)	100

Notes:

- (1) S\$1.875 million of the net proceeds initially allocated for the Group's expansion of its range of pain care services had been reallocated to expand the Group's business operations locally and regionally.
- (2) (a) Utilised for the acquisition of PTL Spine and Orthopedics Private Limited amounting to S\$3.122 million, and (b) startup capital expenses for Alexandra and expenses for East Coast Medical and Paincare Pte. Ltd., Hougang Medical and Paincare Clinic Pte. Ltd., amounting to \$0.728 million.

Save for the Reallocation and as disclosed above, the use of the net proceeds from the Placement is in accordance with the intended use as stated in the announcement dated 17 November 2020.

The Company will make periodic announcements as and when the balance of the net proceeds of the IPO and Placement are materially disbursed.

By Order of the Board

Lee Mun Kam Bernard
Executive Director and Chief Executive Officer
9 February 2024

This announcement has been prepared by the Company and reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "**Sponsor**") in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #18-03B Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.